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Last year, a group from Sirna Therapeutics reportedRibozyme Diagnostics
the development of a target activated ribozyme capableComes of Age of detecting zeptomole (1021M) quantities of hepatitis
C viral RNA in solution [9]. The key to such sensitive
detection properties is that the ribozyme component
parts have absolutely no activity in the absence of theBiosensing ribozymes could soon be used to diagnose
cognate substrate, which differs from previously pub-viral infection. The Kossen group from Sirna Therapeu-
lished allosteric ribozymes whose rates of activity aretics have developed a sensitive, high-throughput
dictated by the rate differences of ribozyme function
means of screening for hepatitis C virus, using their
in the absence and presence of substrate or allosteric
target activated half-ribozyme technology, as reported
modifier. The Sirna group developed a “half-ribozyme”
in the June issue of Chemistry & Biology [1].
approach in which the target RNA itself serves to com-
plete the ribozyme structure. In this ribozyme reaction
A little over two decades ago, the first demonstrations scheme, the multiple turnover class 1 ligase motif devel-
of catalytic RNAs (ribozymes) were reported in the litera- oped by Bartel and colleagues [10] was truncated to
ture [2, 3]. These ribozymes were the cleavage-ligation form a bimolecular substrate RNA, which interacts with
catalyzing Tetrahymena ribosomal RNA intron [3] and the target sequence to allow ligation of one of the sub-
the RNA component of the endoribonuclease RNase strate RNAs containing a 3 cis-diol with a 5 triphos-
P, which catalyzes the site-specific cleavage of the 5 phate containing substrate RNA oligo (Figure 1). This
precursor segment of transfer RNAs [2]. Subsequent to half-ribozyme has no ligase activity in the absence of
these important findings, several other smaller, naturally target RNA and displayed an observed rate increase of
occurring ribozymes with RNA cleavage and ligation 4,000,000-fold when bound to the target.
activities have been described [4], and most recently This exquisitely sensitive ribozyme reporter has been
the RNA component of the large ribosomal subunit has further analyzed for detection of HCV sequences and
been identified as the ribosomal transpeptidase [5]. The high-throughput assays, as reported in last month’s
spectrum of the catalytic capabilities of RNA was greatly Chemistry & Biology by Kossen and coworkers [1]. In this
enhanced following the development of techniques for study, naturally occurring variants of HCV that contain
in vitro evolution of RNAs with new capabilities ranging mismatched pairings to the half-ribozyme were analyzed
from ATP hydrolysis to polymer biosynthesis [6]. An for their effects on ribozyme-mediated ligation of the sub-
important development for evolving biologically and strate RNAs. By extending the base pairing of the ribo-
chemically useful ribozyme functions is the addition of zyme to target the mismatched sequences, these were
allosteric activation functions to ribozymes, which can accommodated without significant kinetic impairment
be mediated by binding of a variety of ligands ranging of target-dependent ligation rates. The variant HCV se-
from small organic molecules through proteins or nu- quences represent greater than 80% of the GenBank
cleic acid oligomers [7, 8]. Allosteric activation is the HCV 5UTR entries, with one of the sequences repre-
key to generating biosensing nucleic acids that can be senting 66%. Thus, the half-ribozyme assay can be gen-
used to monitor any of a number of biological or chemi- erally applied to the majority of HCV clinical samples.
cal processes. Ribo-reporters could in essence become In order to make this assay suitable for clinical appli-
inexpensive replacements for antibodies and other cations, the Sirna investigators collaborated with inves-
tigators from Thermo Electron, Corp., Point of Care andmethods currently in use for diagnostic testing.
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dent ligation mediated by the half-ribozyme resulted in
a target-dependent detection sensitivity several thou-
sand-fold greater than other nucleic acid-activated ribo-
zymes. The sensitivity of the assays using both plat-
forms was about 1 pM, or 3 million molecules of HCV
5 UTR. This sensitivity is somewhat less than what is
generally obtained with immunological assays, which is
in the high femtomolar range. The authors attribute the
diminished sensitivity obtained using the modified oligo
substrates to diminished catalytic efficiency of the half-
ribozyme with these substrates relative to unmodified,
radiolabeled oligos. Performing additional in vitro evolu-
tion experiments with the modified oligos to obtain vari-
ants of the half-ribozyme with increased catalytic effi-
ciency when utilizing these substrates can certainly
enhance the sensitivities of the high-throughput assays.
Overall, the development of the half-ribozyme as a
highly selective and efficient tool for viral RNA diagnos-
tics could have a huge impact on clinical tests for viral
infections. The impact will be in both cost of reagents
and sensitivity of the assays. Once the high-throughput
method for half-ribozyme-mediated ligation can reach
the zeptomole level of sensitivity obtained with unmodi-
fied oligos, this approach will clearly be superior to cur-
rently available immunoassays. The half-ribozyme ap-
Figure 1. Model of Half-Ribozyme-Mediated Ligation
proach could also eclipse PCR-based assays such as
The half-ribozyme (yellow) binds to the target RNA (blue). Binding
are currently being used for HIV and HCV testing. Theof the half-ribozyme to the target results in conformational change
ribozyme approach is not only less expensive, but morethat allows substrates 1 (red) and 2 (green) to bind to the half-
rapid. Moreover, using the optical chip-based platform,ribozyme and carry out the indicated ligation step. For high-
throughput analyses, the substrates have biotin (B) and fluorescein colorimetric readouts should be possible and could be
(F) covalently attached. The ligated oligo is captured on streptavidin- conveniently carried out in a doctor’s office. It is hearten-
coated plates, and the fluorescence is read or detection is mediated ing to see the great promise of ribozymes once again
by use of an anti-fluorescein antibody-peroxidase conjugate (see come to the front, this time in the form of ribozyme-
text).
based diagnostics, as opposed to therapeutics.
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an ELISA-type format. One of the substrate oligos was
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